Abstract:Abstract Homozygosity for the ε4 allele of APOE increases the odds of developing Alzheimer’s by 12 to 15 times relative to the most common ε3;ε3 genotype, and its association with higher plaque loads comports with evidence that APOE ε4 compromises autophagy. The ApoE4 protein specifically binds a cis element (“CLEAR”) in the promoters of several autophagy genes to block their transcription. We used a multifaceted approach to identify a druggable site in ApoE4, and virtual screening of lead-like compounds identified small molecules that specifically bind to this site to impede ApoE4::DNA binding. We validated these molecules both in vitro and in vivo with models expressing ApoE4, including ApoE4 targeted-replacement mice. One compound was able to significantly restore transcription of several autophagy genes and protected against amyloid-like aggregation in a C. elegans AD model. Together, these findings provide proof-of-principle evidence for pharmacological remediation of lysosomal autophagy by ApoE4 via ApoE4-targeted lead molecules that represent a novel tack on neurodegenerative disorders.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the lysosomal autophagy disorder associated with the APOE ε4 allele in Alzheimer's Disease (AD). Specifically, the risk of AD in people carrying the APOE ε4 allele is significantly increased, and compared with APOE ε3, APOE ε4 can impede the autophagy process, leading to the accumulation of pathological features such as amyloid - β (Aβ) plaques and neurofibrillary tangles. The research objective of the paper is to restore the lysosomal autophagy function related to APOE ε4 through targeted small - molecule drugs, thereby reducing the accumulation of these pathological features and providing a new strategy for treating AD. ### Main research contents 1. **Identification of druggable sites of APOE ε4**: - A stable and potentially druggable pocket in the APOE4 protein near the DNA - binding region was predicted by molecular dynamics simulation. 2. **Virtual screening of potential lead compounds**: - High - throughput virtual screening technology was used to screen small molecules from the ChemBridge small - molecule library that can specifically bind to the APOE4 DNA - binding region. 3. **Verification of the effects of lead compounds**: - The effects of these small molecules in restoring autophagy - related gene transcription and reducing Aβ aggregation were verified through in vitro experiments (such as cell culture) and in vivo experiments (such as transgenic mice and nematode models). ### Key findings - **Specific action of CBA2**: - One of the small molecules named CBA2 was proven to be able to effectively restore the transcription of autophagy - related genes in vitro and in vivo models and reduce Aβ aggregation. - CBA2 is highly specific to cells expressing APOE4, and has no obvious effect on cells expressing APOE3. - **Effects of CBA2 in different models**: - In transgenic mice and nematode models, CBA2 can significantly reduce Aβ aggregation and restore the levels of autophagy - related proteins. - These results indicate that CBA2 can restore lysosomal autophagy function by blocking the binding of APOE4 to DNA. ### Conclusion This study provides a proof - of - concept for restoring lysosomal autophagy function by targeting APOE4 and a new direction for the development of new drugs for treating AD. As a potential lead compound, CBA2 shows good therapeutic prospects, especially in reducing Aβ aggregation and restoring autophagy function. This finding is not only of great significance for the treatment of AD, but may also be applicable to other neurodegenerative diseases caused by lysosomal autophagy disorders.

Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer’s disease by targeted small molecules

Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector

ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

The Contributions of the Endolysosomal Compartment and Autophagy to APOEɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk

The Contributions of the Endolysosomal Compartment and Autophagy to APOE ɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk

Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH

Drugs targeting APOE4 that regulate beta‐amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease

APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia

Cell-autonomous Effects of APOE4 in Restricting Microglial Response in Brain Homeostasis and Alzheimer’s Disease

A Biophysical Approach to the Identification of Novel ApoE Chemical Probes

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Peripheral Apoe4 Enhances Alzheimer’s Pathology and Impairs Cognition by Compromising Cerebrovascular Function

Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation